LATIGO BIOTHERAPEUTICS INC
LTGONASDAQ🏆 #2404 by market capUS Equity
$15.76▲ $0.61 (+4.03%)
Pre-market · at closeTrack LTGO
Get earnings, price moves & breaking news on Telegram
24h▲ 4.0%
7d▼ 4.8%
14d▲ 7.1%
30d▼ 13.0%
ytd—
1y—
🏦Market Cap
$948M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $15.19 – $15.96
- 52-Week Range
- $13.50 – $25.93
- Volume (shares)
- 19,590
- Avg Volume (shares)
- —
- Shares Outstanding
- 60.2M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
LATIGO BIOTHERAPEUTICS INC
LTGOFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout LATIGO BIOTHERAPEUTICS INC
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.